hims hers stock - Search News

Novo Nordisk’s stock is rallying

Hosted on MSN · 1h

Stock of the Day: Hims & Hers plunges 27% after saying it will stop selling its Ozempic competitor

With Hims & Hers' main source of growth set to be extinguished, Citi analysts said its full-year guidance appeared "aspirational."

MarketWatch on MSN · 9h

Novo Nordisk’s stock is rallying as Hims & Hers’ stock falters. An Ozempic alternative won’t be available for long.

Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much longer.

Wall Street Journal · 8h

Novo Nordisk Stock Rallies on Weight-Loss Retreat by Hims & Hers

Investors are scrambling to adjust, after the telehealth specialist Hims & Hers said it would stop selling an alternative to Novo Nordisk's Wegovy and Ozempic weight-loss drugs. Hims stock stood about 17% lower at under $42.

Hers, Hims

Barron's on MSN · 10h

Hims & Hers Stock Tumbles Despite Beating Expectations

Hims & Hers Health shares tumbled despite the telehealth provider beating fourth-quarter expectations and offering better-than-expected revenue forecasts for the first quarter and 2025.For the full year 2025,

Insider Monkey on MSN · 5h

Why Hims & Hers (HIMS) Stock Is Tumbling

Hims & Hers (HIMS) stock is sinking 20% today after Eli Lilly (LLY) unveiled significantly cheaper versions of its popular weight-loss drugs today. Additionally, the FDA last week hindered the ability of compounded drugmakers,

Modern Healthcare · 1d

Hims & Hers stock rally stalls as earnings call looms

On Friday, the Food and Drug Administration declared the semaglutide shortage over, sending Hims & Hers shares down 26%.

2h

Hims & Hers tumbles 27% as investors fear uncertainty without compounded weight-loss drugs

Hims & Hers stock tumbled after the company confirmed it would stop selling some compounded weight-loss drugs.

20h

Hims & Hers offers upbeat forecast, but stock slides after hours

Telehealth and wellness platform Hims & Hers on Monday offered a revenue outlook for the year ahead that topped Wall Street’s ...

1don MSN

Hims & Hers shares tumble after company misses on margin, says may stop selling some weight loss drugs

Hims & Hers Health reported fourth-quarter results on Monday that beat analysts’ expectations, but the stock sank in extended ...

19h

Hims & Hers: Post Earnings Drop Is Very Welcomed

Hims & Hers reported a double beat in Q4, but faced an 18% stock drop after hours. Read why this drop is a good opportunity ...

5don MSN

Why Hims & Hers Stock Dropped Today

Raising its price target on the shares to $21, reports The Fly, BofA nonetheless reiterated an "underperform" ( i.e., sell) ...

6hon MSN

These Stocks Are Moving the Most Today: Super Micro, Nvidia, Home Depot, Palantir, Hims & Hers, Eli Lilly, MicroStrategy, and More

Super Micro has until Tuesday to file delayed financial accounts or risk being delisted by the Nasdaq stock exchange, Home ...

11h

Hims & Hers: Capitalizing On The GLP-1 Rush Before The Window Closes (Rating Upgrade)

Hims & Hers projects $725M in GLP-1 weight loss revenue for 2025, a 3.2x increase from 2024. Read why I upgrade HIMS stock ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results